Drugs / h20.19 CAR T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07335328 | Sep 2026 → May 2027 expected | B-cell non-Hodgkin lymphoma | Medical College of Wisconsin | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | h20.19 CAR T cells | “The purpose of this study is to determine the safety of fully human lentiviral 20.19 (h20.19) CAR T cells in patients with relapsed, refractory B-cell malignancies.” NCT07335328 ↗ |
| Modality | Cell therapy | “fully human lentiviral 20.19 (h20.19) CAR T cells” NCT07335328 ↗ |
| Route | Intravenous | “CAR-T cells will be administered at one of two dose levels either fresh or thawed after cryopreservation by IV injection” NCT07335328 ↗ |